ANIK vs HUMA
ANIK: Anika Therapeutics is a regenerative medicine company specializing in hyaluronic acid-based solutions for joint health and soft tissue repair. HUMA: Humacyte engineers acellular tissue-based blood vessels (ATEVs) for vascular access and other applications, with its lead product Symvess in late-stage clinical development.
Side-by-side fundamentals
| Metric | ANIK | HUMA | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $21.42 | $0.718 | |
| Market cap as of 2026-08-10 | $287M | $159M | |
| Net margin as of 2026-08-10 | -3.1% | -3494.6% | ANIK higher |
| Gross margin as of 2026-08-10 | +62.2% | -563.6% | ANIK higher |
| Operating margin as of 2026-08-10 | -4.2% | -6205.7% | ANIK higher |
| ROE as of 2026-08-10 | -2.7% | -1278.9% | ANIK higher |
| ROA as of 2026-08-10 | -2.0% | -85.4% | ANIK higher |
| Debt / equity as of 2026-08-10 | 0.00 | 5.67 | ANIK lower |
| Revenue growth (YoY) as of 2026-08-10 | -2.5% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -0.3% | n/a | |
| Beta as of 2026-08-10 | 0.23 | 2.55 | |
| 1-year return as of 2026-08-07 close | +160.6% | -70.9% | ANIK higher |
Fundamentals: market data, as of 2026-08-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.